Author Archives: Sara Agee Le

May 23, 2020
In The News

There are presently 15 research collaborations underway to enable academic researchers to discover novel therapies for the COVID-19 pandemic and those in the future using advanced artificial intelligence (AI) technology developed by Atomwise Inc. (San Francisco, CA, USA).

Read Article
May 22, 2020
In The News

Atomwise has forged fifteen research collaborations with universities globally to develop broad-spectrum treatments for Covid-19, as well as other coronaviruses.

Read Article
May 21, 2020
FeaturedPress Release

Atomwise democratizes access to its advanced AI technology with 15 research collaborations underway to enable academic researchers to discover novel therapies for this pandemic and those in the future. SAN FRANCISCO–(BUSINESS WIRE)–Atomwise, the leader in using artificial intelligence (AI) for small molecule drug discovery, announced today it has fifteen research collaborations underway with leading global […]

Read Article
May 18, 2020
In The News

A UniSA molecular biologist is working with a world leader in artificial intelligence-based drug discovery to help find a molecule that could prevent the SARS-CoV-2 coronavirus strain causing COVID-19 from infecting human cells.

Read Article
April 14, 2020
Press Release

Atomwise and Hansoh successfully identified potent hit compounds each having unique composition of matter for their first AI discovery program against drug-resistant oncology targets SHANGHAI & SAN FRANCISCO–(BUSINESS WIRE)– Hansoh Pharma (3692:HK), a leading biopharmaceutical company in China, and Atomwise, the leader in artificial intelligence (AI) for drug discovery, today announced the expansion of their strategic partnership for […]

Read Article
March 9, 2020
Press Release

The collaboration will discover and develop up to 13 small molecule programs, initially targeting Pellino proteins to treat multiple indications, including inflammation SAN FRANCISCO & SEONGNAM, South Korea–(BUSINESS WIRE)–Atomwise, the leader in using artificial intelligence (AI) for small molecule discovery, and Bridge Biotherapeutics (KOSDAQ: 288330), a clinical stage biotech company, announced today a research collaboration to launch […]

Read Article